Drug Profile
Minocycline controlled-release - Ortho Dermatologics
Alternative Names: Solodyn; Solodyn Extended Release TabletsLatest Information Update: 16 Oct 2021
Price :
$50
*
At a glance
- Originator Medicis Pharmaceutical Corporation
- Developer Ortho Dermatologics
- Class Amides; Anti-inflammatories; Antiacnes; Antibacterials; Dimethylamines; Eye disorder therapies; Neuroprotectants; Skin disorder therapies; Small molecules; Tetracyclines
- Mechanism of Action Protein 30S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Acne vulgaris
Most Recent Events
- 27 Jul 2017 Valeant Pharmaceuticals International acquired Ortho Dermatologics in 2011 and changed the name of the later to Valeant Dermatology. Subsequently, in July 2017, it was rebranded to Ortho Dermatologics
- 11 Dec 2012 Valeant Pharmaceuticals acquires Medicis Pharmaceutical Corporation
- 30 Aug 2010 The FDA approves minocycline controlled-release at dose strengths of 55mg, 80mg, and 105mg for Acne vulgaris in USA